Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis.

Frontiers in oncology·2021
Same author

The microbiological profile of patients with Fournier's gangrene: A retrospective multi-institutional cohort study.

Urologia·2021
Same author

Rotterdam mobile phone app including MRI data for the prediction of prostate cancer: A multicenter external validation.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2021
Same author

The Influence of Endogenous Testosterone on Incidental Prostate Cancer after Transurethral Prostate Resection.

Urologia internationalis·2021
Same author

Corrigendum to 'Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC)' [European Urology Oncology 3 (2021) 256-263].

European urology oncology·2021
Same author

Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.

Frontiers in endocrinology·2021
Same journal

Change in circulating irisin level and its association with lipid metabolism after exenatide treatment in patients with type 2 diabetes mellitus.

Journal of clinical & translational endocrinology·2026
Same journal

Thyroid cancer and double-strand DNA break repair: The potential role of the MRN complex pathogenic variants.

Journal of clinical & translational endocrinology·2026
Same journal

Temporal changes in circulating miRNAs following gestational diabetes diagnosis: a pilot longitudinal study.

Journal of clinical & translational endocrinology·2026
Same journal

Transition to adult diabetes care for young adults with type 2 diabetes: Challenge and opportunity.

Journal of clinical & translational endocrinology·2026
Same journal

Prevalence of overweight and obesity in a South Texas cystic fibrosis center.

Journal of clinical & translational endocrinology·2026
Same journal

Erratum to "Remnant cholesterol inflammatory index and MASLD in U.S. adults: mediation role of triglyceride-glucose index". [Endocrinology 43 (2026) 100427.

Journal of clinical & translational endocrinology·2026
See all related articles

Related Experiment Video

Updated: Jan 23, 2026

Live Imaging of Chemokine Receptors in Zebrafish Neutrophils During Wound Responses
06:48

Live Imaging of Chemokine Receptors in Zebrafish Neutrophils During Wound Responses

Published on: December 4, 2020

2.8K

Chemokines in hyperthyroidism.

Silvia Martina Ferrari1, Ilaria Ruffilli1, Giusy Elia1

  • 1Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Journal of Clinical & Translational Endocrinology
|June 14, 2019
PubMed
Summary
This summary is machine-generated.

Hyperthyroidism, often caused by Graves' disease (GD), involves overactive thyroid hormone production. Immune cells like Th1 lymphocytes release cytokines and chemokines, driving the autoimmune process in GD.

Keywords:
CXCL10CXCL9ChemokinesCytokinesGraves’ diseaseHyperthyroidism

More Related Videos

Rapid and Robust Analysis of Cellular and Molecular Polarization Induced by Chemokine Signaling
10:03

Rapid and Robust Analysis of Cellular and Molecular Polarization Induced by Chemokine Signaling

Published on: December 12, 2014

8.5K
A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

14.5K

Related Experiment Videos

Last Updated: Jan 23, 2026

Live Imaging of Chemokine Receptors in Zebrafish Neutrophils During Wound Responses
06:48

Live Imaging of Chemokine Receptors in Zebrafish Neutrophils During Wound Responses

Published on: December 4, 2020

2.8K
Rapid and Robust Analysis of Cellular and Molecular Polarization Induced by Chemokine Signaling
10:03

Rapid and Robust Analysis of Cellular and Molecular Polarization Induced by Chemokine Signaling

Published on: December 12, 2014

8.5K
A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

14.5K

Area of Science:

  • Immunology
  • Endocrinology
  • Molecular Biology

Background:

  • Hyperthyroidism is an overproduction of thyroid hormone, with Graves' disease (GD) being the most common cause.
  • Cytokines and chemokines play a role in the pathogenesis of autoimmune thyroid diseases.

Purpose of the Study:

  • To review the role of cytokines and chemokines in hyperthyroidism, particularly in Graves' disease.
  • To explore the potential of Th1 chemokines as therapeutic targets in GD.

Main Methods:

  • Literature review focusing on cytokines and chemokines in hyperthyroidism and GD.
  • Analysis of the interplay between immune cells (Th1 lymphocytes) and thyroid cells (thyrocytes).

Main Results:

  • In Graves' disease, Th1 lymphocytes produce increased levels of interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α).
  • These cytokines stimulate thyrocytes to release Th1 chemokines, perpetuating the autoimmune thyroid condition.
  • Elevated circulating chemokine levels correlate with the active phase of Graves' disease.

Conclusions:

  • Th1 lymphocytes and their cytokine/chemokine production are central to the autoimmune process in Graves' disease.
  • Circulating chemokines may serve as biomarkers for active GD.
  • Th1 chemokines represent a potential novel therapeutic target for managing Graves' disease.